---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-136042"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2024-12-13T23:59:59+00:00"
generated_at: "2026-05-29T03:41:50.622246+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa Therapeutics appoints Eric A. Hughes, M.D., Ph.D. to Board of Directors

## Summary
- Dr. Hughes is Executive VP, Global R&D and Chief Medical Officer at Teva Pharmaceuticals; previously at Vertex, Novartis, BMS.
- Granted option to purchase 44,200 shares vesting monthly over 36 months; annual director fee of $40,000.
- Also eligible for annual stock option grants of 22,100 shares after each annual meeting starting 2025.
- Board determined Dr. Hughes is independent under Nasdaq standards; serves as Class III director until 2027.

## SEC filing metadata
- accession: 0000950170-24-136042
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2024-12-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017024136042/0000950170-24-136042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017024136042/glue-20241211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-136042
- JSON: https://secwatch.observer/filing/0000950170-24-136042.json
- Plain text: https://secwatch.observer/filing/0000950170-24-136042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.